A study involving 78 Chinese NSCLC individuals revealed that those with FAT1 mutations exhibited higher rates of clinical benefit and objective response rates in comparison to individuals without FAT1 mutations (71.4% vs. 22.7%, P = 0.01; 57.1% vs. 15.2%, P = 0.02) after undergoing ICIs. Here, FAT1 is linked to non-small cell lung carcinoma.